FDA Adds Immediate-Release Opioids to REMS to Expand Training, Labeling

International Pharmaceutical Regulatory Monitor
A A
The FDA added immediate-release opioids to its risk evaluation and mitigation strategy (REMS) for opioid analgesics, saying the move will encourage “rational prescribing.”

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00